About InGen
InGen is a company based in Chilly-mazarin (France) founded in 1993 was acquired by Diaxonhit in November 2012. InGen operates in a competitive market with competitors including Horizon Discovery, Quanterix, Arrakis Therapeutics, NanoString and Souzhou Ribo Life Science, among others.
Investors in InGen
InGen has secured backing from 1 investor. Prominent investors backing the company include Diaxonhit.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Fully integrated in vitro diagnostics company specializing in transplantation, infectious diseases and cancer diagnosis | 1997 | exonhit.com | Paris, France |
Investor details for InGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of InGen
3 dated milestones of InGen across 19 years, from founding to its latest funding, stage changes and deals.
- Founded InGen is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Diaxonhit.
Competitors of InGen
InGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Discovery, Quanterix, Arrakis Therapeutics, NanoString and Souzhou Ribo Life Science, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| horizondiscovery.com | 2007 | Cambridge, United Kingdom | $46.29M | 432 | Genetically modified cell lines are developed using AAV gene-editing platform. | |
| quanterix.com | 2007 | Cambridge, United States | $99.5M | 141 | Assay kits for ultra-sensitive biomarker detection are developed. | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| nanostring.com | 2003 | Seattle, United States | $107.93M | 652 | Tools for translational research and molecular diagnosis are developed. | |
| ribolia.com | 2007 | Suzhou, China | $200.79M | – | Nucleic acid drugs are developed via RNA interference technology. | |
| lgcgroup.com | 1842 | Teddington, United Kingdom | – | 901 | Molecular biology reagents and services are supplied to biotech industries. | |
| sourcebioscience.com | 1903 | Nottingham, United Kingdom | – | 273 | Multiple genomic services are provided for analysis and diagnostics. | |
| gpc-biotech.com | 1997 | Planegg, Germany | – | – | Oncology therapies for prostate cancer and lymphoma are developed. | |
| bioneer.com | 1992 | Daejeon, South Korea | – | 3 | Molecular biology products, technologies, and RNAi therapeutics are provided. | |
| beckman.com | 1935 | Brea, United States | – | – | Provider of products for biomedical testing for R&D, diagnostic and commercial applications |
Detailed competitors of InGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ingen
Complete news archive for InGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to InGen
10 companies that operate in the same segment as InGen (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about InGen
InGen was founded in 1993.
InGen is headquartered in Chilly-mazarin, France. It is registered at Chilly-mazarin, Ile-de-france, France.
InGen is engaged in the development, manufacture and marketing of in-vitro diagnostic products for clinical laboratory market. The company offers a range of ELISA kits, Rapid Diagnostic Tests (RDT), Immunodots, Immunofluorescence and Luminex for detection in the fields of infectious diseases and autoimmunity. The diagnostic tests are available for the area of Bacteriology (Respiratory infections, STDs, test for Staphylococcus (Luminex), Helicobacter pylori (ELISA), Lyme and tests for determining vaccination status for pertussis, diphtheria, and tetanus), Virology, Parasitology, Mycology, Auto-immune diseases, reagents for Complement analyses, and Hormonology. In partnership with ONE LAMBDA and CYLEX companies, company offers diagnostic tools for assessing donor-recipient matching (DNA-typing for HLA, KIR and Mica alleles, the detection and identification of anti-HLA antibodies) as well as a personalized monitoring of transplanted patients. In addition, it offers a wide range of tests for detection of PCR (Reaction Polymerase Chain) translocations, clonal rearrangements, and mutations in genes for the detection of leukemia and lymphoma. The company was acquired in 2006 by the biotechnology company IBS (ex AbAg). In 2012, Exonhit bought InGen for 23.1M, and created a new company called Diaxonhit.
InGen's top competitors include Horizon Discovery, NanoString and Quanterix.
InGen has 1 investor. Key investors include Diaxonhit.
Yes. InGen was acquired by Diaxonhit in November 2012.